Q32 Bio has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc.
The asset sale will provide Q32 Bio with additional cash and extend its financial runway into the second half of 2027
Q32 Bio remains focused on advancing bempikibart for alopecia areata, aiming to address significant unmet medical needs
Financial Boost
$12 million in upfront and guaranteed near-term milestone payments will support Q32 Bio's operations and development plans
Potential Revenue
Q32 Bio could receive up to $592 million, including upfront payments, milestone achievements, and future royalties from the sale of ADX-097
Strategic Focus
Q32 Bio retains its tissue-targeted complement inhibitor platform and evaluates options for other early-stage assets
- The sale of ADX-097 strengthens Q32 Bio's financial position and enables a continued focus on bempikibart development
- This transaction aligns with Q32 Bio's strategy to advance innovative therapies for alopecia areata and autoimmune diseases
Q32 Bio's sale of ADX-097 marks a strategic move to bolster financial resources while maintaining dedication to advancing treatments for alopecia areata and related diseases.